Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).
H. Rugo, W. Barry, A. Moreno-Aspitia, et al. (2015). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 181 times. https://doi.org/10.1200/JCO.2014.59.5298
Genome-Wide Meta-Analysis Validates a Roless for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
Katherina C. Chua, Chenling Xiong, Carole Ho, et al. (2020). Clinical pharmacology and therapeutics. Cited 31 times. https://doi.org/10.1002/cpt.1958
A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)
S. Rashkin, Katherina C. Chua, Carole Ho, et al. (2018). Clinical Pharmacology & Therapeutics. Cited 11 times. https://doi.org/10.1002/cpt.1241
Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
Manish R. Sharma, Shailly Mehrotra, E. Gray, et al. (2019). The Journal of Clinical Pharmacology. Cited 9 times. https://doi.org/10.1002/jcph.1559
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
